Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas. Show more
Location: 1017 Ranch Road 620 South, Lakeway, TX, 78734, United States | Website: https://www.anebulo.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
95.73M
52 Wk Range
$0.80 - $3.42
Previous Close
$2.33
Open
$2.38
Volume
6,216
Day Range
$2.23 - $2.38
Enterprise Value
86.98M
Cash
11.63M
Avg Qtr Burn
-1.587M
Insider Ownership
40.54%
Institutional Own.
54.99%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Selonabant (ANEB-001) Details Cannabinoid intoxication | Phase 3 Initiation | |
IV Selonabant (ANEB-001) Details Cannabinoid intoxication | Phase 1 Data readout |